SMO: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of SMO. The page also collects GeneMedi's different modalities and formats products for SMO in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the SMO target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is a G protein-coupled receptor that interacts with the patched protein, a receptor for hedgehog proteins. The encoded protein tranduces signals to other proteins after activation by a hedgehog protein/patched protein complex. [provided by RefSeq, Jul 2010]
Target ID | GM-T66505 |
Target Name | SMO |
Gene ID | 6608,319757,25273,701334,482262,101087567,539308,100033990 |
Gene Symbol and Synonyms | bnb,CRJS,E130215L21Rik,FZD11,Gx,PHLS,SMO,SMOH,smoothened |
Uniprot Accession | Q99835,P97698 |
Uniprot Entry Name | SMO_HUMAN,SMO_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Non-Small Cell Lung Cancer |
Gene Ensembl | ENSG00000128602 |
Target Classification | GPCR |
Pre-made anti-SMO inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-SMO benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-SMO mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-SMO monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody | Detail |
Multi-species SMO/ CRJS/ FZD11 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SMO VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
SMO VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |